Vitalis Therapeutics

Vitalis Therapeutics is a clinical-stage pharmaceutical company focused on improving the safety and efficacy of CNS-targeted therapies through its proprietary Peripheral Restriction (PR) technology. The PR platform utilizes P-glycoprotein (P-gp) inhibitors to modulate the distribution of drugs, specifically increasing the ratio of central nervous system to peripheral exposure. This mechanism allows for the use of lower total doses to achieve therapeutic effects in the brain, thereby significantly reducing systemic side effects. The company's lead candidate, VTS-72, is a novel combination of methadone and a P-gp inhibitor currently in Phase 2 development for opioid use disorder. Vitalis is also advancing programs for alcohol use disorder and treatment-resistant depression, aiming to redefine the standard of care for complex neurological and psychiatric conditions.